Cingulate (CING) Competitors $4.13 +0.45 (+12.23%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$4.20 +0.07 (+1.57%) As of 08/14/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. HURA, ZURA, SAVA, HLVX, COYA, CHRS, MGNX, CLYM, PLRX, and ANIXShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include TuHURA Biosciences (HURA), Zura Bio (ZURA), Cassava Sciences (SAVA), HilleVax (HLVX), Coya Therapeutics (COYA), Coherus Oncology (CHRS), MacroGenics (MGNX), Climb Bio (CLYM), Pliant Therapeutics (PLRX), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Its Competitors TuHURA Biosciences Zura Bio Cassava Sciences HilleVax Coya Therapeutics Coherus Oncology MacroGenics Climb Bio Pliant Therapeutics Anixa Biosciences TuHURA Biosciences (NASDAQ:HURA) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Does the media refer more to HURA or CING? In the previous week, Cingulate had 2 more articles in the media than TuHURA Biosciences. MarketBeat recorded 9 mentions for Cingulate and 7 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.66 beat Cingulate's score of -0.11 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Do analysts recommend HURA or CING? TuHURA Biosciences currently has a consensus price target of $12.67, suggesting a potential upside of 358.94%. Cingulate has a consensus price target of $26.00, suggesting a potential upside of 529.54%. Given Cingulate's higher possible upside, analysts plainly believe Cingulate is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, HURA or CING? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$21.68MN/AN/ACingulateN/AN/A-$15.55M-$8.48-0.49 Which has more volatility and risk, HURA or CING? TuHURA Biosciences has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.74, meaning that its share price is 174% less volatile than the S&P 500. Do insiders & institutionals hold more shares of HURA or CING? 0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is HURA or CING more profitable? TuHURA Biosciences' return on equity of 291.69% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A 291.69% 122.09% Cingulate N/A -229.78%-142.28% SummaryTuHURA Biosciences and Cingulate tied by winning 6 of the 12 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulateMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.37M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.4920.4930.2725.74Price / SalesN/A356.37459.75115.79Price / CashN/A43.0338.2159.48Price / Book1.788.608.846.15Net Income-$15.55M-$54.65M$3.25B$265.06M7 Day Performance-0.96%5.86%3.72%2.60%1 Month Performance-8.63%8.86%5.86%2.83%1 Year Performance-13.96%13.33%30.25%25.58% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.2693 of 5 stars$4.13+12.2%$26.00+529.5%+123.2%$19.37MN/A-0.4920Short Interest ↑Gap UpHigh Trading VolumeHURATuHURA Biosciences1.8902 of 5 stars$2.59+7.9%$12.67+389.1%N/A$104.83MN/A0.00N/ANews CoverageGap UpZURAZura Bio3.8549 of 5 stars$1.46-2.7%$14.33+881.7%-47.1%$102.56MN/A-2.093News CoveragePositive NewsEarnings ReportSAVACassava Sciences2.0656 of 5 stars$2.29+8.0%$54.50+2,279.9%-89.8%$102.41MN/A-1.5330News CoverageEarnings ReportGap DownHLVXHilleVax1.5801 of 5 stars$2.07+1.5%$2.00-3.4%+23.8%$102.29MN/A-0.9620High Trading VolumeCOYACoya Therapeutics1.8195 of 5 stars$6.34+4.1%$16.50+160.3%+18.0%$101.86M$3.69M-5.936News CoverageEarnings ReportAnalyst ForecastCHRSCoherus Oncology4.2941 of 5 stars$0.87-1.1%$4.68+439.6%-25.5%$101.77M$266.96M-0.77330MGNXMacroGenics4.3387 of 5 stars$1.64+3.8%$5.33+225.2%-51.5%$99.68M$152.43M-1.84430Trending NewsEarnings ReportCLYMClimb Bio3.5357 of 5 stars$1.70+17.2%$9.00+429.4%N/A$97.99MN/A-0.719Earnings ReportGap UpHigh Trading VolumePLRXPliant Therapeutics3.7648 of 5 stars$1.70+7.6%$13.31+683.1%-86.8%$96.99M$1.58M-0.4790Gap DownANIXAnixa Biosciences2.8683 of 5 stars$3.26+8.3%$9.00+176.1%-4.2%$96.96M$210K-8.585 Related Companies and Tools Related Companies TuHURA Biosciences Competitors Zura Bio Competitors Cassava Sciences Competitors HilleVax Competitors Coya Therapeutics Competitors Coherus Oncology Competitors MacroGenics Competitors Climb Bio Competitors Pliant Therapeutics Competitors Anixa Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access